New Senolytic Drugs Force Cancer's Zombie Cells to Self-Destruct
Scientists found drugs that kill senescent 'zombie cells' by blocking their key survival protein, shrinking tumors in mice.
20 articles
Scientists found drugs that kill senescent 'zombie cells' by blocking their key survival protein, shrinking tumors in mice.
New research reveals senescent cells have both harmful and protective roles, pushing anti-aging science toward targeted removal strategies.
A new DNA-based treatment blocks the PCSK9 protein, cutting LDL cholesterol by nearly 50% while avoiding common statin side effects.
A small molecule called UNI418 shuts down cancer cells' DNA repair machinery, making drug-resistant tumors vulnerable to treatment again.
Scientists discover D-cysteine selectively targets cancer cells by disrupting their energy production without harming normal cells.
Researchers discovered why fibrolamellar carcinoma resists immunotherapy and found an existing drug can free trapped T cells to fight it.
Experimental PCAI compounds blocked over 90% of pancreatic cancer cell migration and triggered self-destruction by hyperactivating tumor growth pathways.
New study shows PCSK9 inhibitor prevents cardiovascular events in high-risk diabetes patients without existing heart disease.
Bemnifosbuvir blocks hepatitis E replication in lab tests, offering hope for treating a virus that kills 70,000 people annually.
A UCLA study found that aggressive small cell cancers lacking the RB gene depend on protein E2F3 to survive — blocking it stopped tumor growth in lab models.
McGill scientists boosted NK cell cancer-killing power using reversible drug treatment, targeting leukemia, glioblastoma, and triple-negative breast cancer.
Disabling the NFIL3 protein prevents CAR T cell exhaustion, boosting tumor-fighting power in animal models of hard-to-treat cancers.
Plant compounds naturally target multiple cancer pathways simultaneously, offering advantages over pharmaceutical approaches.
New compound AP503 activates GPR133 receptor to rebuild bone density in mice, offering hope for millions with osteoporosis.
A new Oxford tool using 5.6 million patient records shows serious statin muscle side effects are rare, yet 60% of eligible patients skip the drug.
A once-undruggable cancer driver has finally been targeted, cutting death risk by 60% in a landmark 500-patient trial.
Redesigned immunotherapy injected into one tumor triggered complete cancer remission in 2 of 12 patients, with untreated tumors also disappearing.
A newly identified molecule called SLAMF6 exhausts cancer-fighting T cells from within — and blocking it may revive failed immunotherapies.
New trial data reveals AstraZeneca's experimental in vivo CAR-T therapy showed early responses in multiple myeloma patients but resulted in one death.
When tumors hide from killer T cells, they accidentally expose themselves to helper T cells that trigger a lethal iron-driven cell death process.